Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (23297)	3/23/2007 1:23:17 PM
From: NeuroInvestment	Read Replies (2) \| Respond to of 52153

Two notes: 1) The ALXA inhalable Compazine is intended as a migraine rescue therapy, when triptans etc fail, and the alternative is a trip to the ER. That kind of (hopefully) very intermittent use should give the FDA less concern re: TD, though TD is a somewhat unpredictable phenomenon. 2) I had the same question about the MOA action vis-a-vis analgesia. I talked to Jim Cassell (who used to be at Neurogen before Alexza) about this at length, and while the MOA (for analgesia) still seems very obscure to me, they felt pretty confident about the analgesic effects, stating that IM Compazine/prochlorperazine is frequently used in ER settings to abort persistent migraines. FWIW. Harry NeuroInvestment